These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

767 related articles for article (PubMed ID: 31684964)

  • 1. Recent updates on CAR T clinical trials for multiple myeloma.
    Lin Q; Zhao J; Song Y; Liu D
    Mol Cancer; 2019 Nov; 18(1):154. PubMed ID: 31684964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR T-cell therapy against B-cell maturation antigen in multiple myeloma.
    Cohen AD
    Clin Adv Hematol Oncol; 2018 Dec; 16(12):804-806. PubMed ID: 30843888
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T-cell therapy: is it prime time in myeloma?
    Sidana S; Shah N
    Blood Adv; 2019 Nov; 3(21):3473-3480. PubMed ID: 31714964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
    Feng D; Sun J
    Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CARs in the Lead Against Multiple Myeloma.
    Ormhøj M; Bedoya F; Frigault MJ; Maus MV
    Curr Hematol Malig Rep; 2017 Apr; 12(2):119-125. PubMed ID: 28233151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
    Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
    Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
    [No Abstract]   [Full Text] [Related]  

  • 8. Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.
    Timmers M; Roex G; Wang Y; Campillo-Davo D; Van Tendeloo VFI; Chu Y; Berneman ZN; Luo F; Van Acker HH; Anguille S
    Front Immunol; 2019; 10():1613. PubMed ID: 31379824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity.
    Globerson Levin A; Rawet Slobodkin M; Waks T; Horn G; Ninio-Many L; Deshet Unger N; Ohayon Y; Suliman S; Cohen Y; Tartakovsky B; Naparstek E; Avivi I; Eshhar Z
    Cancer Immunol Res; 2020 Dec; 8(12):1485-1495. PubMed ID: 33008840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model.
    Ng BD; Rajagopalan A; Kousa AI; Fischman JS; Chen S; Massa A; Elias HK; Manuele D; Galiano M; Lemarquis AL; Boardman AP; DeWolf S; Pierce J; Bogen B; James SE; van den Brink MRM
    Blood; 2024 Jul; 144(2):171-186. PubMed ID: 38579288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.
    Cohen AD
    Am Soc Clin Oncol Educ Book; 2018 May; 38():e6-e15. PubMed ID: 30231373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
    Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
    Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy.
    Grywalska E; Sosnowska-Pasiarska B; Smok-Kalwat J; Pasiarski M; Niedźwiedzka-Rystwej P; Roliński J
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-Cells.
    Shah UA; Smith EL
    Cancer J; 2019; 25(3):208-216. PubMed ID: 31135528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
    Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
    J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
    Garfall AL; Stadtmauer EA; Hwang WT; Lacey SF; Melenhorst JJ; Krevvata M; Carroll MP; Matsui WH; Wang Q; Dhodapkar MV; Dhodapkar K; Das R; Vogl DT; Weiss BM; Cohen AD; Mangan PA; Ayers EC; Nunez-Cruz S; Kulikovskaya I; Davis MM; Lamontagne A; Dengel K; Kerr ND; Young RM; Siegel DL; Levine BL; Milone MC; Maus MV; June CH
    JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
    Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q
    Front Immunol; 2021; 12():720571. PubMed ID: 34421924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
    Huang H; Wu HW; Hu YX
    J Zhejiang Univ Sci B; 2020 Jan.; 21(1):29-41. PubMed ID: 31898440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting B-cell maturation antigen in multiple myeloma.
    Tai YT; Anderson KC
    Immunotherapy; 2015; 7(11):1187-99. PubMed ID: 26370838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.